Consequently, targeting miRNA-155 or other factors involved in CTLA-4 regulation specifically in Treg cells, without affecting T cells, has the potential to enhance the effectiveness of immunotherapy in treating melanoma [175]. Here, CTLA4 is linked to melanoma.